Thinking October 22nd, 2026

Is your medical device ready for Human Factors validation testing?

Maria Mawhinney
By
Maria Mawhinney Human Factors Engineer
3 people with laptops and a medical device sat at a table

Human factors (HF) validation testing is the evaluation that confirms that the intended users of a medical device can safely and effectively operate it under realistic use conditions. FDA Guidance (Applying Human Factors and Usability Engineering to Medical Devices guidance, issued August 3, 2026) emphasizes this evaluation as a required step in verifying that use-related risks have been adequately addressed before commercialization.

Unfortunately, device readiness gaps can often threaten HF validation outcomes. Those gaps – which indicate a device or its supporting evidence is not actually ready for final testing – could be related to an incomplete definition of the intended users and use environments, noncomprehensive risk documentation, lack of prior formative evaluations, inadequate residual risk analysis, or immaturity of the user interface design. Therefore, from a Human Factors perspective, how can a manufacturer determine whether a device is ready for this evaluation?

In this blog, Maria Mawhinney, Human Factors Engineer, and Kate Cox, Director of Human Factors, will go over some common gaps Ensera Design has observed when we are contracted to conduct HF validation studies. As the user-centered design and human factors engineering processes are long and complex, this list is non-exhaustive.

Intended users and use environment

Do you know who the intended users of the device are? How about the intended environment where the device is going to be used? A manufacturer preparing for an HF validation study knows the device’s primary users and use environment, but other individuals may perform important tasks during the device lifecycle.

For example, a surgeon may operate an electrosurgical vessel-sealing device during a procedure, while other operating room personnel retrieve the device from storage, inspect the packaging and expiration date, open the sterile packaging using aseptic technique, and transfer the device to personnel in the sterile field. Others may be responsible for disposing of the device after the procedure or sending it out for reprocessing. All these individuals and their tasks need to be considered in the use specification and use-related risk analysis.

When defining the intended user(s) for your device, consider mapping out the workflow of how the device is handled from its retrieval to disposal, including maintenance and cleaning procedures, if applicable. This will help with identifying all of the users of the device.

The same principle applies when defining use environments. For example, a diagnostic device used by emergency medical technicians may be operated in various settings including busy public places such as restaurants, streets, parks, patients’ homes, or moving ambulances. All these environments may have distinctive differences in terms of lighting, noise levels, and available space, which can affect device usability. Vehicle motion can create vibrations and surface instability, potentially influencing how safely and effectively the device is used. These conditions should be considered when identifying use-related hazards and designing representative HF validation scenarios.

photo of surgery

Use-related risk analysis (URRA)

Have you analyzed the device’s use-related risks? A URRA documents the use-related hazards and hazardous situations related to the user interface, the tasks (including critical tasks), potential use errors that could occur in those situations, and measures implemented to control risk.

The process of generating the URRA should start in the early stages of device development and be updated as the device, use specification, and user interface evolve. Each task with the device needs to be defined and analyzed for foreseeable use errors and their potential consequences. This can be accomplished through research into known use issues and observations made in formative evaluations.

One objective of the URRA is to identify critical tasks – user tasks which, if performed incorrectly or not performed at all, would or could cause serious harm to the patient or user, where harm is defined to include compromised medical care (FDA, 2026). Human Factors validation testing should evaluate all identified critical tasks in representative use scenarios with the intended users in order to provide evidence that the implemented risk control measures are effective.

post-it-notes on a desk

Formative evidence

Have you run at least one formative study with your device to identify and improve usability problems ahead of design freeze? FDA guidance does not dictate the specific number of formative studies required during medical device development, but formative evaluation is an important part of an iterative Human Factors engineering process, increasing confidence that a device will perform successfully in validation.

Through formative evaluation, the manufacturer can identify device pain points and areas where the user interface needs to be improved, with representative users providing direct feedback and invaluable suggestions. However, a primary objective of the evaluation should be to observe participant performance and use problems. Findings should be incorporated into the use-related risk analysis and used to guide user interface improvement.

Even a device that appears ‘straightforward’ and ‘simple’ can benefit from a formative evaluation. Intended users may interact with the device in ways the development team did not anticipate, particularly when there are inconsistencies with their current workflows and experiences. The example below illustrates how an apparently straightforward selection error can reveal a design problem.

Parker Hannifin / Porter Porter MIDAS equipment in test lab

Example: use error description

A physician completed a patient’s medication order but selected ‘Delete’ instead of ‘Save’. The software deleted the order immediately and returned back to the main screen without requesting confirmation or indicating that the deletion had occurred. The participant could not find the order and indicated that they were unsure how to proceed.

Subjective feedback: “I had no idea it was deleted because no message appeared after I selected ‘Delete.’ I clicked it accidentally. On each page of the form, ‘Next’ appears in the lower-right corner, so I expected the ‘Submit’ button to appear there as well. Instead, ‘Submit’ was in the lower-left corner. When I thought I was moving forward, I deleted the order. The system should have confirmed the deletion or notified me that the order had been deleted.”

Root Cause Analysis:

  • Location of the submit button – the location of the submit button was in the lower left corner instead of the right corner. The right corner for the submit button made more sense to the participant because it signifies to them that they are moving forward.
  • Lack of completed action information – the lack of an information screen about the order being deleted left the participant uninformed that the entry was deleted.
  • Lack of confirmation screen – the lack of the confirmation screen asking to approve the action of deletion prevented the participant from recovering from their mistake.

Clicking the wrong button in the above scenario appears careless, but the interface makes the error both foreseeable and easy to commit – especially when the user is working quickly.

This type of UI design flaw would get identified in formative studies which could then be mitigated by a simple UI design change of relocating the ‘Submit’ button, adding a confirmation screen after the user selects to either delete or submit the form, and a final information screen indicating whether the form was successfully saved or deleted.

Residual-risk analysis

It is widely understood that there is always some residual risk remaining after risk control measures are in place. However, prior to starting the HF validation study, the manufacturer should analyze whether the implemented risk controls bring the residual risk levels to an acceptable level, or if further risk controls are necessary.

The HF validation study provides evidence of effectiveness, and therefore the team should be confident that the current controls will be adequate prior to executing the study and potentially discovering that additional modifications and retesting are required. However, when there are uncertainties, utilizing a formative / pre-summative study with a smaller sample size is an excellent tool to either provide confidence or insights for what needs to be remedied prior to starting HF validation.

3 women sat at a table looking at ostomy bags

User-interface maturity

The FDA’s Applying Human Factors and Usability Engineering to Medical Devices guidance, issued August 3, 2026, states that the ‘user interface should be sufficiently final and representative of the version intended for commercialization’.

This means that the Agency expects HF validation testing to be conducted using relevant hardware, software, display controls, alarms, accessories, packaging, labeling, instructions for use, and training as commercially equivalent.

For example, if instructions are planned to be accessed electronically through a QR code, the HF validation study should provide the QR code and a representative means of accessing the electronic instructions rather than substituting printed instructions without justification.

Similarly, if the training program includes instructional videos, the videos and their delivery should be representative of the planned commercial training. If the device does not fulfill the appropriate UI maturity, the outcome of the HF validation testing will not be considered reliable as the UI tested did not represent the final version intended for market release. This outcome will become a subject of deficiency during the FDA review process.

When considering starting the process of HF validation testing, the manufacturer should reflect on several aspects of their device readiness. Specifically, a clear and comprehensive definition of intended users and use environments should be confirmed, risk documentation should be generated and detailed, all risk controls should be in place and effectiveness confirmed by formative evaluations, and the entirety of the UI should be deemed as representative to what is intended at market release.

team working with software

How Ensera Design can help

Our Human Factors team can help you determine whether your device is genuinely ready for HF validation. We support teams in identifying device readiness gaps across intended users and environments, use-related risk analysis, formative testing, residual-risk evaluation and user-interface maturity, then provide the study design, recruitment, moderation, validation and reporting expertise needed to move forward with greater confidence.

 

Maria Mawhinney, Human Factors Engineer at Ensera Design, has recently co-moderated a roundtable on “Managing Borderline Validation Outcomes” at the 7th Edition US Medical Device Human Factors and Usability Engineering Conference in Boston on 21 October 2026. Click here to learn more: 7th Edition US Medical Device Human Factors Conference 2026

Speak to our experts about your own unique challenge.

Speak to our experts about your own unique challenge.

Whether you’re looking to identify your next innovation priority, or keen to accelerate development of an existing concept, we can help you move forward with momentum.